Nonradiographic axial spondyloarthritis

Novartis announced the ongoing Phase 3 PREVENT trial examining use of secukinumab in patients with non-radiographic axial spondyloarthritis has met its primary endpoint of ASAS40.

Remission is unlikely in non-radiographic axial spondyloarthritis without biologic therapy. Adding certolizumab to background therapy can lead to significant improvements in disease activity compared to placebo, researchers find.

The COAST-X trial evaluated the safety and efficacy of ixekizumab for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA).

Certolizumab pegol (Cimzia) is the first FDA-approved treatment for the condition.

Be aware that changes in geometry, bone mineral density, and micro-structure appear early in the disease course of axSpA.

New treatment guidelines for non-radiographic axial spondyloarthritis call for treatment with TNF blockers if NSAIDs fail.